MIMIC has identified three closely interdependent scientific work packages to further develop and improve organs on chip technology.

Microchip on a fingertip.

WP1: enomic engineering of human disease models suitable for organs on chips incorporation.

One of the major advantages of organs on chips technology is the possibility to generate more accurate in vitro disease models, which can be exploited for research and drug screening.

Consequently, this work package will establish three in vitro disease models based on genomically engineered cell lines using state of the art CRISPR technology. 

WP2: development of ''organs on chips'' model.

Cell lines mimicking disease models will be incorporated into suitable PDMS-based organs on chips models to exploit this technique for further basic research of underlying disease mechanisms.

In addition, cell lines generated in this work package will be incorporated into MIMETAS organ on chips technology (OrganoPlates®) with the aim to develop in vitro models suitable for high throughput drug screenings.

WP3: drug development and end-user validation of organs on chips models.

Drug development requires the identification of suitable target molecules as well as extensive testing for drug toxicity. Industry often applies high throughput screenings to identify genes involved in disease mechanisms or to test drug efficiency and toxicity.

At the final stage of all research projects, organ on chips created by MIMIC fellows will be tested for high throughput screenings.

A global reputation

Sheffield is a research university with a global reputation for excellence. We're a member of the Russell Group: one of the 24 leading UK universities for research and teaching.